Accessibility StatementSkip Navigation Scelfo to strengthen and scale Lucid's market access infrastructure ahead of key upcoming reimbursement milestones—including Medicare coverage for EsoGuard—and to accelerate commercial coverage expansion NEW YORK, Sept. 16, 2025 /PRNewswire/ --Â Lucid Diagnostics Inc.(Nasdaq: LUCD)Â ("Lucid" or the "Company"), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the appointment of Danielle Scelfo ...